COVAXIN

COVAXIN is well tolerated with no serious adverse events in Phase I trials

Read more

COVID-19 expedites India’s focus on innovation within pharma: GlobalData 

Read more

Team of 70 Ambassadors and High Commissioners visit Bharat Biotech, discuss COVAXIN

Read more

Bharat Biotech seeks EUA for Covaxin

Read more

Modi visits key vaccine facilities as COVID-19 case load surges

Read more

Homegrown COVID-19 vaccine final trials may conclude within two months: India

Read more

Bharat Biotech commences Phase III trials for COVAXIN 

Read more

AMU targets 1000 volunteers for phase-III trial of Covaxin

Read more

Covaxin may get launched in February 2021: ICMR scientist

Read more

Bharat Biotech plans Covaxin launch in second quarter of 2021, post requisite approvals

Read more